European Journal of Case Reports in Internal Medicine

 

The European Journal of Case Reports in Internal Medicine is an official journal of the European Federation of Internal Medicine (EFIM). The journal wants to promote the practice of internal medicine in Europe. Its aim is to provide a forum to internal medicine doctors.
EJCRIM welcomes papers describing unusual or complex cases and case series that an internist may encounter in everyday practice. Case series are also welcomed as long as they demonstrate the appropiateness of a therapeutical approach or unusual manifestation of a disease.
The journal would also consider brief reasoned reports of issues relevant to the practice of Internal Medicine, as well as Abstracts submitted to scientific meetings of European societies of Internal Medicine.

EJCRIM is peer-reviewed with single-blind review and freely accessible to all.

 
Patrícia Afonso Mendes, Emilia Trigo, Rui Pina, Paulo Martins, Jorge Pimentel
Rakshita Chandrashekar, Monoj Kumar Konda, Vishal Gupta, Jagadeesh K Kalavakunta
Katya Muscat, Ruth Galea, Malcolm Vella
Faye Pais, Mohamed Fayed, Timothy Evans
Mohamad Jaffer Abdalkhalig Mustafa, Mohamed Bakri Mohamed, Amjad Hayat
Giagkos Michael Lavranos, Demetra Kouma, Antonis Deveros, Georgia Pigiotou, Georgios Samanis, Chrysostomos Zintilis
Paschalis Sidiras, Frédéric Vandergheynst, Laurine Verset, Hazim Kadhim, Muhammad Shahnawaz Soyfoo
Gizem Zorlu, Seyit Uyar, Hakan Ozer, Murat Esin, Selin Kir, Abdullah Tokuc, Süleyman Dolu, Feyzi Bostan, Ayhan Hilmi Cekin

Pulmonary Sarcoidosis in Behçet's Disease Treated with Adalimumab

Marlene Louro, Teresa Vaio, Jorge Crespo, Rui Santos, Armando Carvalho
Published: 22/02/2017

ABSTRACT

TNF-α antagonists are used to treat various rheumatic diseases including sarcoidosis. However, there have been increasing reports of sarcoidosis in relation to treatment using these drugs. The pathogenesis of this reaction remains unknown.
This is a report of a clinical case of sarcoidosis in Behçet's disease (DB) with mucocutaneous and intestinal involvement in treatment using adalimumab, with improvement after anti-TNF suspension and corticosteroid therapy.

VIEW THE ARTICLE